Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease.
Xavier RoblinGérard DuruKonstantinos PapamichaelAdam S CheifetzSandy KwiatekAnne-Emmanuelle BergerMathilde BarrauLouis WaeckelStéphane NanceyStephane PaulPublished in: Journal of clinical medicine (2023)
In our real-life cohort, ATU was identified as an independent predictor of LOR to ustekinumab in patients with IBD.
Keyphrases